Verastem (VSTM) Long-Term Investments (2011 - 2021)

Verastem's (VSTM) quarterly Long-Term Investments came in at $6.0 million in Q2 2021, little changed quarter-over-quarter from $6.0 million in Q1 2021.

Verastem (VSTM) Long-Term Investments (2011 - 2021) Analysis & Trends

Verastem's Long-Term Investments history runs 7 years deep, the most recent figure standing at $6.0 million for Q2 2021.

  • On a quarterly basis, Long-Term Investments changed N/A year-over-year to $6.0 million in Q2 2021; TTM through Jun 2021 was $6.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $6.0 million, changed N/A from the prior year.
  • Long-Term Investments held at $6.0 million in Q2 2021 per VSTM's latest filing, from $6.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $6.0 million in Q1 2021 and bottomed at $6.0 million in Q2 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 505,194.89
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.75 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 9.79 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Verastem 166.09 Mn -31.73 Mn 15.90 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2021 5.99 Mn
Mar 31, 2021 6.00 Mn
Dec 31, 2020 6.00 Mn
Mar 31, 2015 4.00 Mn
Jun 30, 2014 5.76 Mn
Mar 31, 2014 8.23 Mn
Dec 31, 2013 22.34 Mn
Sep 30, 2013 30.34 Mn
Jun 30, 2013 20.56 Mn
Mar 31, 2013 17.69 Mn
Dec 31, 2012 34.94 Mn
Sep 30, 2012 50.58 Mn
Jun 30, 2012 65.60 Mn
Mar 31, 2012 68.27 Mn
Dec 31, 2011 8.99 Mn